A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2001
11/28/2001	EP1157702A1 Compositions comprising DNA Damaging Agents and p53
11/28/2001	EP1157130A1 Identification of genes having a role in the presentation of diabetic nephropathy
11/28/2001	EP1157123A1 Stable recombinant influenza viruses free of helper viruses
11/28/2001	EP1157122A1 Anti-neoplastic compositions and uses thereof
11/28/2001	EP1157114A2 Genetically engineered retroviral vector particles capable of infecting non-dividing cells
11/28/2001	EP1157108A1 Methods and reagents for inhibiting proliferation of smooth muscle cells
11/28/2001	EP1157105A1 Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
11/28/2001	EP1157104A2 Pyk2 binding proteins
11/28/2001	EP1157103A2 Production of helper dependent adenovirus vectors based on use of endonucleases
11/28/2001	EP1157038A1 Cloning of a p2y-like 7tm receptor (axor17)
11/28/2001	EP1157035A1 Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
11/28/2001	EP1156833A1 Metastasis models using green fluorescent protein (gfp) as a marker
11/28/2001	EP1156832A1 Use of lithium (li?+ ) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
11/28/2001	EP1156820A1 Vascular endothelial growth factor-2
11/28/2001	EP1156812A1 Multiparticulate formulation
11/28/2001	EP1156789A1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
11/28/2001	EP1023085A4 Human embryonic germ cell line and methods of use
11/28/2001	EP0845032B1 Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
11/28/2001	EP0727223B1 Polyamino acid oligonucleotide carrier
11/28/2001	EP0708671B1 Drug delivery
11/28/2001	EP0698108B1 Adenoviral vectors of animal origin and use thereof in gene therapy
11/28/2001	CN1324406A DNA molecules encoding MUC-1 and use thereof in tumor vaccination
11/28/2001	CN1324405A Novel G protein-coupled receptor proteins, DNAS thereof and ligands to the same
11/28/2001	CN1324403A PRV-1 gene and the use thereof
11/28/2001	CN1324401A Nucleic acid sequence for potentiating the expression of useful gene and method therefor
11/28/2001	CN1324400A Method of screening for large offspring syndrome
11/28/2001	CN1324251A Method of stimulating prosaposin receptor activity
11/28/2001	CN1324243A Method for treating inflammatory inflammatory diseases using heat shock proteins
11/27/2001	US6323333 Mouse EDG1
11/27/2001	US6323329 Nucleic acid sequences of genes encoding high mobility group proteins
11/27/2001	US6323318 Human protein kinases hYAK3-2
11/27/2001	US6323184 Arteriovenous and venous graft treatments: methods and compositions
11/27/2001	US6323179 Chicken GNRH analogs and uses thereof in regulation of fertility and pregnancy
11/27/2001	US6323031 Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells
11/27/2001	US6323029 Therapeutic, diagnostic, and research applications for the modulation of glycogen synthase kinase 3 beta expression
11/27/2001	US6323026 Mutations in the KCNE1 gene encoding human mink which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
11/27/2001	US6323024 Plasmids for the expression of heterologus genes; for use in treatment and prevention of viral diseases
11/27/2001	US6323019 Design of novel highly efficient HIV based packaging systems for gene therapy
11/27/2001	US6323003 Compositions and methods for activating genes of interest
11/27/2001	US6322987 Carbamate-derivatized nucleosides and oligonucleosides
11/27/2001	US6322982 Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
11/27/2001	US6322978 Repeat polymorphism in the frataxin gene and uses therefore
11/27/2001	US6322976 Compositions and methods of disease diagnosis and therapy
11/27/2001	US6322804 Implantable biocompatible immunoisolatory vehicle for the delivery of selected therapeutic products
11/27/2001	US6322780 Marek's disease virus vaccines for protection against Marek's disease
11/27/2001	US6322536 Minimally invasive gene therapy delivery and method
11/27/2001	CA1341323C Method and composition for preventing growth and replication of cancer cells that express the core structure of a mucin-type glycoprotein
11/26/2001	CA2346163A1 Complex for transferring an anionic substance of interest into a cell
11/26/2001	CA2322554A1 Cell culture and method for production
11/24/2001	CA2309235A1 Fusion polypeptides
11/23/2001	CA2309324A1 Gene that imparts selective proliferation activity
11/22/2001	WO2001088203A1 Cloning of rhadinovirus genome and methods for its use
11/22/2001	WO2001088199A2 Identification and modulationof of a t helper-1 and t helper-2 cells
11/22/2001	WO2001088191A1 A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿
11/22/2001	WO2001088160A2 Vectors for dna delivery
11/22/2001	WO2001088141A2 Synthetic gagpol genes and their uses
11/22/2001	WO2001088135A2 G-protein coupled receptor proteins and nucleic acids encoding same
11/22/2001	WO2001088134A2 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	WO2001088131A1 Regulation of mt1-mmp activity
11/22/2001	WO2001088128A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	WO2001088125A1 MUTATION IN THE β2 NICOTINIC ACETYLCHOLINE RECEPTOR SUBUNIT ASSOCIATED WITH NOCTURNAL FRONTAL LOBE EPILEPSY
11/22/2001	WO2001088116A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods
11/22/2001	WO2001088108A1 Neuronal serine-threonine protein kinase
11/22/2001	WO2001088106A2 Novel deoxyribonucleside kinase enzyme multi-substrate variants
11/22/2001	WO2001088017A1 Polypeptide derivatives and nucleic acid carriers containing the same
11/22/2001	WO2001087978A2 Human abc transporter and its use
11/22/2001	WO2001087961A1 A new polypeptide-human pax protein 11.4 and the polynucleotide encoding it
11/22/2001	WO2001087938A2 Polynucleotide sequence encoding a putative cell adhesion molecule
11/22/2001	WO2001087935A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
11/22/2001	WO2001087934A2 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
11/22/2001	WO2001087923A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087350A2 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	WO2001087348A2 Multifunctional nanodevice platform
11/22/2001	WO2001087346A2 Dendritic cells loaded with toxic substances
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087314A1 Methods and compositions for promoting angiogenesis using monocytes
11/22/2001	WO2001087312A1 Polyethylene glycol (peg) polymers for the promotion of angiogenesis
11/22/2001	WO2001087310A1 Process for reducing antibody response against xenografts
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001042442A3 Activation of endogenous genes by genomic introduction of a replicon
11/22/2001	WO2001036977A3 Identification of disease markers involving mass-based-separation
11/22/2001	WO2001036650A3 An oncolytic adenovirus
11/22/2001	WO2001036476A3 Ing2, an iaps associated cell cycle protein, compositions and methods of use
11/22/2001	WO2001035991A3 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
11/22/2001	WO2001034809A3 Staphylococcus epidermidis nucleic acids and proteins
11/22/2001	WO2001034805A3 Human vanilloid receptor gene
11/22/2001	WO2001034185A3 Induction of mucosal immunity by vaccination via the skin route
11/22/2001	WO2001032891A3 Human lipase
11/22/2001	WO2001031036A3 Modified viral surface proteins which bind to cells of tumor vasculature
11/22/2001	WO2001030989A3 Method for creating divergent populations of nucleic acid molecules and proteins
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001023597A9 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	WO2001007637B1 Conditionally controlled, attenuated hiv vaccine

1 ... 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 ... 870